Clinical Trials Browser

Phase 1/2 × Fibrosis × Erlotinib Hydrochloride × Clear all

NCT02273362 2024-03-26

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Phase 1/2 Completed

25 enrolled 10 charts

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular